In the BioHarmony Drug Report Database

"Preview" Icon

Vibegron

Gemtesa (vibegron) is a small molecule pharmaceutical. Vibegron was first approved as Gemtesa on 2020-12-23. It is used to treat overactive urinary bladder in the USA. The pharmaceutical is active against beta-3 adrenergic receptor. Gemtesa’s patents are valid until 2030-12-01 (FDA).

 

Trade Name

 

Gemtesa
 

Common Name

 

vibegron
 

ChEMBL ID

 

CHEMBL2107826
 

Indication

 

overactive urinary bladder
 

Drug Class

 

Beta 3 adrenoreceptor agonist

Image (chem structure or protein)

Vibegron structure rendering